A Fine Addition: Finerenone in the Evolving Landscape of Heart Failure with Preserved Ejection Fraction

Overview

Journal Heart Fail Rev

Date 2024 Oct 30

PMID 39476221

Authors

Rami Halaseh

Andrew J Sauer

Orly Vardeny

Mario Enrico Canonico

Josephine Harrington

Jana Svetlichnaya

Andrew P Ambrosy

Affiliations

Soon will be listed here.

References

McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M . 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36):3599-3726. DOI: 10.1093/eurheartj/ehab368. View

Heidenreich P, Bozkurt B, Aguilar D, Allen L, Byun J, Colvin M . 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022; 79(17):1757-1780. DOI: 10.1016/j.jacc.2021.12.011. View

Pitt B, Zannad F, Remme W, Cody R, CASTAIGNE A, Perez A . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10):709-17. DOI: 10.1056/NEJM199909023411001. View

Zannad F, McMurray J, Krum H, Van Veldhuisen D, Swedberg K, Shi H . Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2010; 364(1):11-21. DOI: 10.1056/NEJMoa1009492. View

Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martinez Ubago J . Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004; 110(10):1263-8. DOI: 10.1161/01.CIR.0000140973.60992.9A. View

Borlaug B, Paulus W . Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2010; 32(6):670-9. PMC: 3056204. DOI: 10.1093/eurheartj/ehq426. View

Butler J, Fonarow G, Zile M, Lam C, Roessig L, Schelbert E . Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014; 2(2):97-112. PMC: 4028447. DOI: 10.1016/j.jchf.2013.10.006. View

Pitt B, Pfeffer M, Assmann S, Boineau R, Anand I, Claggett B . Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370(15):1383-92. DOI: 10.1056/NEJMoa1313731. View

Pfeffer M, Claggett B, Assmann S, Boineau R, Anand I, Clausell N . Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2014; 131(1):34-42. DOI: 10.1161/CIRCULATIONAHA.114.013255. View

10.

de Denus S, OMeara E, Desai A, Claggett B, Lewis E, Leclair G . Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. N Engl J Med. 2017; 376(17):1690-1692. PMC: 5590224. DOI: 10.1056/NEJMc1612601. View

11.

Cohen J, Schrauben S, Zhao L, Basso M, Cvijic M, Li Z . Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. JACC Heart Fail. 2020; 8(3):172-184. PMC: 7058514. DOI: 10.1016/j.jchf.2019.09.009. View

12.

Kolkhof P, Joseph A, Kintscher U . Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy. Pharmacol Res. 2021; 172:105859. DOI: 10.1016/j.phrs.2021.105859. View

13.

Kintscher U, Bakris G, Kolkhof P . Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2021; 179(13):3220-3234. DOI: 10.1111/bph.15747. View

14.

Bakris G, Agarwal R, Anker S, Pitt B, Ruilope L, Rossing P . Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020; 383(23):2219-2229. DOI: 10.1056/NEJMoa2025845. View

15.

Pitt B, Filippatos G, Agarwal R, Anker S, Bakris G, Rossing P . Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021; 385(24):2252-2263. DOI: 10.1056/NEJMoa2110956. View

16.

Agarwal R, Filippatos G, Pitt B, Anker S, Rossing P, Joseph A . Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022; 43(6):474-484. PMC: 8830527. DOI: 10.1093/eurheartj/ehab777. View

17.

Agarwal R, Joseph A, Anker S, Filippatos G, Rossing P, Ruilope L . Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2021; 33(1):225-237. PMC: 8763180. DOI: 10.1681/ASN.2021070942. View

18.

Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H . Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013; 34(31):2453-63. PMC: 3743070. DOI: 10.1093/eurheartj/eht187. View

19.

Solomon S, McMurray J, Vaduganathan M, Claggett B, Jhund P, Desai A . Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024; 391(16):1475-1485. DOI: 10.1056/NEJMoa2407107. View

19.

Fox G, Nhung N, Cam Binh N, Hoa N, Garden F, Benedetti A . Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam. N Engl J Med. 2024; 391(24):2304-2314. DOI: 10.1056/NEJMoa2314325. View